Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Siddharth J. Modi & Vithal M. Kulkarni. (2022) Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, ‘DFG-out’ inhibitors. Journal of Biomolecular Structure and Dynamics 40:12, pages 5712-5727.
Read now
Read now
Robert Musiol. (2017) An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opinion on Drug Discovery 12:6, pages 583-597.
Read now
Read now
Haijun Zhang. (2015) Apatinib for molecular targeted therapy in tumor. Drug Design, Development and Therapy 9, pages 6075-6081.
Read now
Read now
Sufia Butt Hassan, Jesper Freddie Sørensen, Barbara Nicola Olsen & Anders Elm Pedersen. (2014) Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacology and Immunotoxicology 36:2, pages 96-104.
Read now
Read now
Articles from other publishers (11)
Indu Passi, Koushal Billowria, Bhupinder Kumar & Pooja A. Chawla. (2023) Tivozanib: A New Hope for Treating Renal Cell Carcinoma. Anti-Cancer Agents in Medicinal Chemistry 23:5, pages 562-570.
Crossref
Crossref
Hye-Young Min & Ho-Young Lee. (2022) Molecular targeted therapy for anticancer treatment. Experimental & Molecular Medicine 54:10, pages 1670-1694.
Crossref
Crossref
Fernando Auria-Luna, Eugenia Marqués-López, Eduardo Romanos, Vanesa Fernández-Moreira, M. Concepción Gimeno, Isabel Marzo & Raquel P. Herrera. (2020) Novel ureido-dihydropyridine scaffolds as theranostic agents. Bioorganic Chemistry 105, pages 104364.
Crossref
Crossref
Rong Huang, Xiu-Ling Shi, Yun-Fei Wang, Fei Yang, Ting-Tao Wang & Cun-Xu Peng. (2019) Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: A case report. World Journal of Clinical Cases 7:22, pages 3881-3886.
Crossref
Crossref
V. Grünwald & M.-O. Grimm. (2018) Erstlinientherapie des mRCC: ein UpdateFirst-line therapy of mRCC: an update. Der Onkologe 24:10, pages 809-816.
Crossref
Crossref
Feng Li, Zhichao Liao, Chao Zhang, Jun Zhao, Ruwei Xing, Sheng Teng, Jin Zhang, Yun Yang & Jilong Yang. (2018) Apatinib as targeted therapy for sarcoma. Oncotarget 9:36, pages 24548-24560.
Crossref
Crossref
Chao Wei, Shen Wang, Zhangqun Ye & Zhiqiang Chen. (2018) Efficacy of targeted therapy for advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. International braz j urol 44:2, pages 219-237.
Crossref
Crossref
Junjie Lan, Lan Huang, Huayong Lou, Chao Chen, Tangjingjun Liu, Shengcao Hu, Yao Yao, Junrong Song, Jun Luo, Yazhou Liu, Bin Xia, Lei Xia, Xueyi Zeng, Yaacov Ben-David & Weidong Pan. (2018) Design and synthesis of novel C14-urea-tetrandrine derivatives with potent anti-cancer activity. European Journal of Medicinal Chemistry 143, pages 1968-1980.
Crossref
Crossref
Alessia Mira, Virginia Morello, Maria Virtudes Céspedes, Timothy Perera, Paolo M. Comoglio, Ramon Mangues & Paolo Michieli. (2017) Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Oncotarget 8:24, pages 38193-38213.
Crossref
Crossref
Gayle Smythe. 2016. Growth Factors and Cytokines in Skeletal Muscle Development, Growth, Regeneration and Disease. Growth Factors and Cytokines in Skeletal Muscle Development, Growth, Regeneration and Disease
161
183
.
Joan Minguet, Katherine H. Smith, Carsten P. Bramlage & Peter Bramlage. (2015) Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. Cancer Chemotherapy and Pharmacology 76:2, pages 219-233.
Crossref
Crossref